MENU 
The summary EQA timetable can be downloaded HERE. The calendar below includes all EQA open/close dates and other GenQA events.
EQA Catalogue Groups
(Click on a colour/icon to filter calendar entries)
Clinical Genetics and Genetic Counselling
Genomic and Inherited Disorders
Haematological Neoplasms
Individual Competency Assessment
Molecular Newborn Screening
Molecular Pathology
Multidisciplinary team (MDT) working
Pharmacogenomics
Preimplantation Genetic Testing (PGT)
Reproductive Genomics
Sample Handling
Technical (Next Generation Sequencing)
Variant Classification
Viral Sequencing
Other Events
GenQA EQA Enrolment Event
GenQA EQA Distribution Event
GenQA webinar
Conference
GenQA workshop
GenQA Participant meeting
GenQA office closed
Other
| «prev August 2026 next»
| ||||||
| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
| Sun 26 | Mon 27 | Tue 28 | Wed 29 | Thu 30 | Fri 31 | Sat 1 |
| Sun 2 | Mon 3 | Tue 4 | Wed 5 | Thu 6 | Fri 7 | Sat 8 |
| Sun 9 | Mon 10
2026 Distribution 13
2026 Trio Sequencing - Prenatal - OPENS Testing Period: 8 weeks | Tue 11 | Wed 12 | Thu 13 | Fri 14
2026 Preimplantation genetic testing for monogenic disorders (PGT-M) - CLOSES | Sat 15 |
| Sun 16 | Mon 17
2026 Distribution 14
2026 Pharmacogenomics: Aminoglycoside ototoxicity - OPENS Testing Period: 6 weeks
2026 Pharmacogenomics: APOE (pilot) - OPENS Testing Period: 6 weeks
2026 Pharmacogenomics: CYP2C19 - OPENS Testing Period: 6 weeks
2026 Pharmacogenomics: DPYD - OPENS Testing Period: 6 weeks
2026 Pharmacogenomics: panel (pilot) - OPENS Testing Period: 6 weeks
2026 Pharmacogenomics: TPMT and NUDT15 - OPENS Testing Period: 6 weeks
2026 Pharmacogenomics: UGT1A1 (pilot) - OPENS Testing Period: 6 weeks | Tue 18 | Wed 19 | Thu 20 | Fri 21 | Sat 22 |
| Sun 23 | Mon 24
2026 SARS-CoV-2 sequencing - Distribution 6101 - round 2 - OPENS Testing Period: 6 weeks from sample distribution | Tue 25 | Wed 26 | Thu 27 | Fri 28
2026 Ataxia & Hereditary Spastic Paraplegia (HSP) - CLOSES
2026 Charcot Marie Tooth disease (CMT) and related sensory and motor neuropathies - CLOSES
2026 Eye disorders - CLOSES
2026 Familial colorectal cancer and polyposis - CLOSES
2026 Familial endocrine tumour predisposition disorders - CLOSES
2026 Familial Hypercholesterolaemia (FH) - CLOSES
2026 Gastroenterology and hepatology disorders - CLOSES
2026 Hereditary Breast and Ovarian Cancer (HBOC) disorders - CLOSES
2026 Inborn Errors of Metabolism (IEM) - CLOSES
2026 Mitochondrial disease - CLOSES
2026 Muscular dystrophies - CLOSES
2026 Neurodegenerative disorders - CLOSES
2026 Neurofibromatosis and rasopathies - CLOSES
2026 Parathyroid and Calcium Regulation disorders - CLOSES
2026 Primary Immunodeficiency disorders (PID) - CLOSES
2026 Skeletal dysplasia (including Osteogenesis Imperfecta) - CLOSES
2026 Variant Validation - CLOSES | Sat 29 |
| Sun 30 | Mon 31
2026 Distribution 15
2026 Bone Marrow Failure syndromes (pilot) - OPENS Testing Period: 12 weeks
2026 Chronic Lymphocytic Leukaemia (CLL) - OPENS Testing Period: 6 weeks
2026 Chronic Lymphocytic Leukaemia (CLL) IGHV mutation status - OPENS Testing Period: 6 weeks
2026 Chronic Lymphocytic Leukaemia (CLL) TP53 mutation analysis - OPENS Testing Period: 6 weeks
2026 Lymphoma - OPENS Testing Period: 6 weeks
2026 Optical Genome Mapping (OGM) - haematological neoplasms (pilot) - OPENS Testing Period: 6 weeks
2026 Inherited cytopenias (pilot) - OPENS Testing Period: 12 weeks | Tue 1 | Wed 2 | Thu 3 | Fri 4 | Sat 5 |
7872
NEWSLETTER SIGN UP